Advanced Biliary Tract Carcinoma

Oncology
3
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 1 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
1
Biospecimen CollectionPhase 21 trial
Active Trials
NCT07405086Not Yet Recruiting160Est. Dec 2028
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
DurvalumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03704480Active Not Recruiting106Est. Dec 2025
Molecular Partners
Molecular PartnersSchlieren-Zurich, Switzerland
1 program
1
MP0317 + Gemcitabine + Cisplatine + DurvalumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT07036380Recruiting75Est. Nov 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Knight TherapeuticsBiospecimen Collection
Molecular PartnersMP0317 + Gemcitabine + Cisplatine + Durvalumab
AstraZenecaDurvalumab

Clinical Trials (3)

Total enrollment: 341 patients across 3 trials

NCT07405086Knight TherapeuticsBiospecimen Collection

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Start: Feb 2026Est. completion: Dec 2028160 patients
Phase 2Not Yet Recruiting
NCT07036380Molecular PartnersMP0317 + Gemcitabine + Cisplatine + Durvalumab

MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma

Start: Dec 2025Est. completion: Nov 202975 patients
Phase 2Recruiting
NCT03704480AstraZenecaDurvalumab

Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.

Start: Nov 2018Est. completion: Dec 2025106 patients
Phase 2Active Not Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
8m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
8m ago

Office Administrator

SystImmune
9m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
19m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
23m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
23m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 341 patients
Monoclonal Antibody is the dominant modality (100% of programs)
3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)